Q2042
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- 2021 Status Change: Add procedure or modifier code
- Effective Date: 2019-01-01
- Medicare Coverage Status: Carrier Judgement
- BETOS Classification: Other drugs
Medicare has not assigned a fee schedule for this code
Q2041
Q2043 